Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor
Article first published online: 16 DEC 2011
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society
British Journal of Pharmacology
Volume 165, Issue 2, pages 436–454, January 2012
How to Cite
Bertini, R., Barcelos, L., Beccari, A., Cavalieri, B., Moriconi, A., Bizzarri, C., Di Benedetto, P., Di Giacinto, C., Gloaguen, I., Galliera, E., Corsi, M., Russo, R., Andrade, S., Cesta, M., Nano, G., Aramini, A., Cutrin, J., Locati, M., Allegretti, M. and Teixeira, M. (2012), Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor. British Journal of Pharmacology, 165: 436–454. doi: 10.1111/j.1476-5381.2011.01566.x
- Issue published online: 16 DEC 2011
- Article first published online: 16 DEC 2011
- Accepted manuscript online: 30 JUN 2011 01:45PM EST
- Received; 31 January 2011; Revised; 26 May 2011; Accepted; 7 June 2011
Figure S1 Pharmacokinetic profile of DF 2156A in the mouse. Plasma concentrations of DF 2156Y (the free acid of DF 2156A) were determined after a single s.c. administration of DF 2156A (10 mg·kg−1). Plasma levels of DF 2156Y were determined at different times after treatment as described in Supplementary Text. Each experimental determination is the mean ± SD of three mice plasma samples.
|BPH_1566_sm_FS1.tif||796K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.